Stabilized Urinary Biogenic Amines Measured in Clinical Chemistry Laboratories
|
By LabMedica International staff writers Posted on 23 Feb 2021 |

Image: The Dionex CoulArray Coulometric Array Detector (Photo courtesy of Thermo Fisher Scientific).
Carcinoid tumors are rare neuroendocrine tumors deriving from enterochromaffin cells secreting serotonin. The measurement of urinary 5-hydroxyindoleacetic acid (5-HIAA), the main product of serotonin metabolism, is used for the diagnosis and follow-up for this tumor.
Neuroblastomas are neoplasms that arise from neural crest-derived cell precursors of postganglionic sympathetic neurons and are characterized by excessive production of catecholamines (CATs). 5-HIAA, vanillylmandelic (VMA), homovanillic acid (HVA), catecholamines and metanephrines are produced in excess by catecholamine-producing tumors.
Medical Biochemists at the Lausanne University Hospital (Lausanne, Switzerland) obtained 22 urine spots from enrollees (aged 25 to 65, 50% males) and were aliquoted in 250 µL polypropylene tubes. The pH of urines was immediately measured using pH indicator strips. Each of the 22 urine samples was split into three sub-samples, one of which was supplemented by 5 mL of 6 M HCl per liter of urine (“HCl urine”), the second by 10 grams citrate per liter of urine (“citrate urine”), and the third was unmodified (“native urine”).
All the analytical methods used throughout the study were the routine methods from the laboratory and were fully validated. 5-HIAA, VMA, and HVA were measured in one aliquot by LC-MS/MS using a dilute-and-shoot sample preparation. The CATs were quantified in the third aliquot using the RECIPE catecholamine kit (Munich, Germany) using a 5600A electrochemical CoulArray system coupled to an isocratic HPLC (ESA-Dionex, Sunnyvale, CA, USA). CATs were also quantified by LC-MS/MS.
The scientists reported that that catecholamines degradation was prevented by HCl and citrate and that 5-HIAA was degraded in five out of 22 samples collected with HCl. All biogenic amines were efficiently stabilized by citrate for four weeks at 22 °C, except epinephrine (48 hours at 4 °C, or four weeks at −20 °C). Sodium citrate did not cause quantification or analytical artifacts concerns.
The authors concluded that sodium citrate is a non-hazardous alternative to HCl for patients to send unfrozen urine samples to the laboratory which may safely store the sample for four weeks. The team proposes to replace HCl by sodium citrate for stabilizing urinary 5-HIAA, VMA, HVA, catecholamines and total metanephrines as a safe alternative for clinical chemistry laboratory and patients. The study was published in the March, 2021 issue of the journal Clinica Chimica Acta.
Related Links:
Lausanne University Hospital
RECIPE
ESA-Dionex
Neuroblastomas are neoplasms that arise from neural crest-derived cell precursors of postganglionic sympathetic neurons and are characterized by excessive production of catecholamines (CATs). 5-HIAA, vanillylmandelic (VMA), homovanillic acid (HVA), catecholamines and metanephrines are produced in excess by catecholamine-producing tumors.
Medical Biochemists at the Lausanne University Hospital (Lausanne, Switzerland) obtained 22 urine spots from enrollees (aged 25 to 65, 50% males) and were aliquoted in 250 µL polypropylene tubes. The pH of urines was immediately measured using pH indicator strips. Each of the 22 urine samples was split into three sub-samples, one of which was supplemented by 5 mL of 6 M HCl per liter of urine (“HCl urine”), the second by 10 grams citrate per liter of urine (“citrate urine”), and the third was unmodified (“native urine”).
All the analytical methods used throughout the study were the routine methods from the laboratory and were fully validated. 5-HIAA, VMA, and HVA were measured in one aliquot by LC-MS/MS using a dilute-and-shoot sample preparation. The CATs were quantified in the third aliquot using the RECIPE catecholamine kit (Munich, Germany) using a 5600A electrochemical CoulArray system coupled to an isocratic HPLC (ESA-Dionex, Sunnyvale, CA, USA). CATs were also quantified by LC-MS/MS.
The scientists reported that that catecholamines degradation was prevented by HCl and citrate and that 5-HIAA was degraded in five out of 22 samples collected with HCl. All biogenic amines were efficiently stabilized by citrate for four weeks at 22 °C, except epinephrine (48 hours at 4 °C, or four weeks at −20 °C). Sodium citrate did not cause quantification or analytical artifacts concerns.
The authors concluded that sodium citrate is a non-hazardous alternative to HCl for patients to send unfrozen urine samples to the laboratory which may safely store the sample for four weeks. The team proposes to replace HCl by sodium citrate for stabilizing urinary 5-HIAA, VMA, HVA, catecholamines and total metanephrines as a safe alternative for clinical chemistry laboratory and patients. The study was published in the March, 2021 issue of the journal Clinica Chimica Acta.
Related Links:
Lausanne University Hospital
RECIPE
ESA-Dionex
Latest Clinical Chem. News
- AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
- Compact Prenatal Screening System Expands Access to Preeclampsia Testing
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Channels
Molecular Diagnostics
view channel
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreLiquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
Detecting and monitoring cancer often requires repeated tissue biopsies, which are invasive and not always feasible. Liquid biopsy offers a less invasive way to track disease over time, but many assays... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







